TrialBlood2021

Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies.

Michael U Callaghan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.